🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "huge turning point" in the effort against increasingly resistant strains of the bacteria, according to researchers.

An International Challenge

The sexually transmitted infection are on the rise around the world, with figures suggesting in excess of 82 million infections per year. Especially elevated rates are observed in Africa and nations within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have reached a record high, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune step in the reality of rising global incidence, escalating drug resistance and the extremely scarce treatment choices at this time.”

Public health authorities are deeply concerned about the increase in treatment-resistant strains. The World Health Organization has classified it as a "priority pathogen". Recent surveillance showed that resistance to key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Treatment Options Secure Approval

Zoliflodacin, alternatively called Nuzolvence, was cleared by the American regulatory agency in mid-December for treating gonorrhoea. This disease can lead to significant complications, including infertility. Researchers believe that focused deployment of this new drug will help hinder the emergence of superbugs.

Gepotidacin, developed by the drugmaker GSK, was also approved in concurrent days. This drug, which is additionally indicated for urinary tract infections, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

This new treatment stemmed from a unique collaborative effort for medication research. The non-profit organisation GARDP worked alongside the pharmaceutical company Innoviva to see it through.

“This approval represents a huge turning point in the treatment of highly resistant gonorrhoea, which previously has been outpacing medical innovation.”

Research Study Data and Global Access

According to results detailed in a major medical journal, zoliflodacin cured more than 90% of uncomplicated infections. This puts it on an comparable level with the typical regimen, which uses two antibiotics. The trial included over 900 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the rights to make available and distribute the drug in a wide range of developing nations.

Clinicians directly involved have expressed positive views. The availability of a single-dose, oral treatment of this kind is hailed as a "critical tool" for public health efforts. This is viewed as crucial to lessen the impact of the infection for people and to prevent the spread of untreatable gonorrhoea worldwide.